During Q3, digital health's funding fell 36% quarter-over-quarter and 72% from its all-time high during last year's Q2. The primary driver of this reduction is macro market trends, experts said, though digital health companies need to tie their services more directly to value to get funding in the future.
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup's Series A round of financing.
By Amanda James Thursday, November 3, 2022 8:04 PM
This lawsuit centers on the leadership of the Arnhold Institute for Global Health, which is part of the Icahn School of Medicine, and the hiring decisions made by the school's dean, Dr. Dennis Charney, as well as alleged discrimination from other leaders.
MedCrypt, a San Diego-based provider of cybersecurity solutions for medical devices, recently closed a $25 million Series B funding round. The startup sells its software to medical devices manufacturers so they can enhance the security of their products, which range from pacemakers to CT scanners.
By Marissa Plescia Thursday, November 3, 2022 5:10 PM
Hint Health acquired AeroDPC, a software company and electronic medical record for direct primary care clinics. As a result, Hint will release a new product in 2023 that combines tools from both companies.
By Joel Theisen Thursday, November 3, 2022 5:01 PM
Let's tear down the silos that transport seniors through the classic stages of hospitals, rehab, assisted living, and nursing homes. Value-based care or better yet, global risk, has a way of disintegrating these silos. If providers want to get paid, they must collaborate. That means instead of treating a singular issue, we must reach out to the rest of the ecosystem, coordinating treatment and driving together toward a meaningful outcome.
By Marissa Plescia Thursday, November 3, 2022 2:28 PM
The financing round was led by Heritage Group, and included participation from the investment arms of insurers, like Cigna Ventures and Trinnovate Ventures of Blue Cross Blue Shield Arizona. It brings Valera's total financing amount to about $70 million.
By Frank Vinluan Thursday, November 3, 2022 12:16 PM
Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex's drug addresses a different central nervous system target that the biotech believes could offer an edge.
Here are three points to consider for any healthcare system that aims to develop apps that enjoy high adoption and, as a result, improve patients' lives.
Today, the pharmaceutical industry is undergoing a rapid and dynamic transformation. Successful contract management plays an instrumental role in navigating this landscape.
No comments